Related Experiment Videos
Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy
Hanna Nieznanska1, Magdalena Bandyszewska1, Krystyna Surewicz2
1Department of Biochemistry, Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur Str., 02-093 Warsaw, Poland.
Abstract:
Soluble form of the prion protein (PrP) has been previously shown to interact with amyloid-β (Aβ) peptides, suppressing their fibrillization as well as toxicity, which indicates that this protein may play a protective role in Alzheimer's disease (AD). The shortest known PrP fragment retaining all of these properties corresponds to physiologically generated proteolytic polypeptide PrP23-110/111, called N1. Here we have identified two N1-derived synthetic peptides, encompassing residues 23-50 (PrP23-50) and 90-112 (PrP90-112), which bind to Aβ1-42 protofibrillar oligomers as well as amyloid fibrils. We found that, akin to N1, the abovementioned synthetic peptides not only reduce the initial rate of Aβ fibrillization, but also alter the aggregation pathway of Aβ, inhibiting formation of protofibrillar oligomers and facilitating amorphous aggregation. Furthermore, our data show that N1, PrP23-50 and PrP90-112 protect cultured hippocampal neurons from neurotoxic effects of Aβ oligomers, preventing oligomers-induced retraction of neurites and loss of cell membrane integrity. The above PrP fragments can also attenuate neuronal intake of Aβ. Our results strongly suggest that synthetic peptides such as PrP23-50 and PrP90-112 can be useful in designing a novel class of therapeutics in AD.
Insights
Synthetic prion protein (PrP) fragments, PrP23-50 and PrP90-112, show protective effects against amyloid-beta (Aβ) toxicity in Alzheimer's disease (AD) models. These peptides inhibit Aβ aggregation and shield neurons from damage, suggesting therapeutic potential for AD.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Soluble prion protein (PrP) interacts with amyloid-beta (Aβ) peptides, inhibiting their fibrillization and toxicity.
- This interaction suggests a protective role for PrP in Alzheimer's disease (AD).
- The N1 fragment (PrP23-110/111) is the shortest known PrP form with these protective properties.
Purpose of the Study:
- To identify and characterize synthetic peptides derived from the N1 fragment of PrP.
- To evaluate the ability of these synthetic peptides to inhibit Aβ aggregation and toxicity.
- To assess the neuroprotective potential of these peptides in Alzheimer's disease models.
Main Methods:
- Identification of two N1-derived synthetic peptides: PrP23-50 and PrP90-112.
- Assessment of peptide binding to Aβ1-42 protofibrillar oligomers and amyloid fibrils.
- Analysis of Aβ fibrillization kinetics and aggregation pathway modulation.
- Evaluation of neuroprotection in cultured hippocampal neurons against Aβ oligomer toxicity.
- Measurement of neuronal uptake of Aβ.
Main Results:
- PrP23-50 and PrP90-112 bind to Aβ1-42 oligomers and fibrils.
- These peptides reduce the rate of Aβ fibrillization and alter the aggregation pathway, inhibiting protofibrillar oligomer formation.
- PrP fragments protect hippocampal neurons from Aβ oligomer-induced neurotoxicity, including neurite retraction and membrane damage.
- The peptides attenuate neuronal uptake of Aβ.
Conclusions:
- Synthetic peptides PrP23-50 and PrP90-112 mimic the protective effects of the N1 PrP fragment.
- These peptides inhibit Aβ aggregation and neurotoxicity, offering a potential therapeutic strategy for Alzheimer's disease.
- The findings suggest that these synthetic peptides could form the basis for novel AD therapeutics.